Subtle hardware, big impact - Hologic Brevera in everyday breast biopsy

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-20, 06:56. Details in the imprint.

With the Brevera breast biopsy system, Hologic turns a usually tense moment in the mammography suite into a more controlled routine, with the console humming quietly while tissue cores appear on screen seconds after sampling. For radiologists, that immediacy changes the room. For patients, it can quietly shorten a frightening procedure.

What Brevera changes in the room

In a typical stereotactic biopsy, there is a lot of choreography: separate vacuum console, specimen tray, imaging system, back and forth between screens. With Brevera, Hologic bundles vacuum-assisted biopsy, real-time imaging, and automated tissue handling in one workflow-focused platform.

The radiologist hears a single system draw the sample, then almost immediately sees the cores appear as images for verification. That reduces the need to reposition or re-sample when the target is clearly captured. Staff move less, cables are tidier, the room feels more focused.

Integrated vacuum and imaging workflow

Technically, Brevera is built as a vacuum-assisted breast biopsy system that pairs with Hologic’s mammography and 3D tomosynthesis units. The needle takes multiple tissue cores through a single insertion, while the vacuum draws them into a closed chamber instead of open dishes.

Crucially, the system routes those cores past an integrated imaging window. The console snaps X-ray images of the specimens within seconds, allowing the radiologist to confirm microcalcifications or lesion tissue without leaving the patient. That near-real-time feedback is what Hologic highlights to clinics looking to cut procedure time.

Less handling, more hygiene

For technologists, one of the quiet but convincing benefits is how little they need to handle the samples. Instead of lifting tiny cores from a tray with forceps, the automated chamber collects and presents them in an orderly way, ready for transfer to pathology cassettes.

That closed-path approach reduces the risk of dropping or misplacing tissue fragments and helps maintain a cleaner field. In a small biopsy room, with anxious patients and time pressure, that reduction in fiddly steps can feel surprisingly liberating.

Patient experience and procedure time

From the patient’s perspective, Brevera does not change the compression or needle puncture itself. The breast is still fixed in the unit, the needle still clicks. Where it helps is duration: fewer reinsertions and quicker confirmation can shorten the time in compression.

Radiology teams that move from older, multi-step setups to an integrated platform often report that biopsy slots become easier to schedule. More predictable procedure times and less room turnover work are not glamorous, but they matter in busy breast centers trying to avoid backlogs.

Where Brevera fits in Hologic’s line-up

Hologic positions Brevera alongside its Affirm prone and upright biopsy systems and its Selenia Dimensions mammography platforms, as part of a tightly knit breast-health ecosystem. The idea is simple: keep patient, image, and tissue in one continuous digital chain.

That ecosystem play is consistent with Hologic’s broader strategy in women’s health diagnostics, where the company leans on hardware, software, and consumables that lock together. For hospitals, that can be a comfortingly unified environment - or a constraint, depending on procurement philosophy.

Company context and share listing

For Hologic, every Brevera console in the field typically means a long tail of biopsy needle and consumable sales, which is appealing for a company built on recurring diagnostic revenue. Breast health sits alongside molecular diagnostics and surgical products as a core pillar.

Shares of Hologic (US4364401012) trade on Nasdaq in US dollars.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.